Currently, marketed ROCK inhibitors approved for glaucoma treatment are Ripasudil (K-115; brand name: Glanatec) and netarsudil (AR-13324; brand name: Rhopressa), which target both ROCK1 and ROCK2. Here, ROCK1 is linked to glaucoma.